BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 927 filers reported holding BAXTER INTL INC in Q4 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $733,012,000 | -3.6% | 16,531,615 | +3.5% | 0.11% | -7.6% |
| Q3 2016 | $760,280,000 | +5.6% | 15,972,269 | +0.4% | 0.12% | +0.9% |
| Q2 2016 | $719,653,000 | +11.4% | 15,914,479 | +1.2% | 0.12% | +9.3% |
| Q1 2016 | $646,175,000 | +14.6% | 15,729,664 | +6.4% | 0.11% | +15.1% |
| Q4 2015 | $563,815,000 | +20.1% | 14,778,910 | +3.4% | 0.09% | +13.4% |
| Q3 2015 | $469,512,000 | -59.6% | 14,292,591 | -14.0% | 0.08% | -56.1% |
| Q2 2015 | $1,161,930,000 | +15.7% | 16,615,621 | +13.3% | 0.19% | +19.9% |
| Q1 2015 | $1,004,595,000 | -7.5% | 14,665,618 | -1.1% | 0.16% | -10.3% |
| Q4 2014 | $1,086,612,000 | -4.1% | 14,826,201 | -6.1% | 0.17% | -8.4% |
| Q3 2014 | $1,133,208,000 | -6.8% | 15,789,442 | -6.1% | 0.19% | -5.9% |
| Q2 2014 | $1,215,314,000 | -0.3% | 16,809,322 | +1.4% | 0.20% | -3.8% |
| Q1 2014 | $1,219,320,000 | +8.2% | 16,571,347 | +2.3% | 0.21% | +5.5% |
| Q4 2013 | $1,126,777,000 | +9.3% | 16,200,968 | +3.2% | 0.20% | 0.0% |
| Q3 2013 | $1,030,892,000 | -9.0% | 15,693,294 | -4.0% | 0.20% | -13.1% |
| Q2 2013 | $1,132,384,000 | – | 16,347,393 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |